Boris Stoeber

Microdermics, Inc. designs, builds, tests, and manufactures proprietary hollow metal microneedles that will eliminate the need for hypodermic needles for many therapeutics and traditional intramuscular vaccinations. It focuses on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. The company was founded by Sahan Ranamukharachchi, Iman Mansoor, Urs O. Häfeli, and Boris Stoeber in June 2014 and is headquartered in Vancouver, Canada.

Microdermics, Inc. designs, builds, tests, and manufactures proprietary hollow metal microneedles that will eliminate the need for hypodermic needles for many therapeutics and traditional intramuscular vaccinations. It focuses on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. The company was founded by Sahan Ranamukharachchi, Iman Mansoor, Urs O. Häfeli, and Boris Stoeber in June 2014 and is headquartered in Vancouver, Canada.

Microdermics, Inc. designs, builds, tests, and manufactures proprietary hollow metal microneedles that will eliminate the need for hypodermic needles for many therapeutics and traditional intramuscular vaccinations. It focuses on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. The company was founded by Sahan Ranamukharachchi, Iman Mansoor, Urs O. Häfeli, and Boris Stoeber in June 2014 and is headquartered in Vancouver, Canada.

Microdermics, Inc. designs, builds, tests, and manufactures proprietary hollow metal microneedles that will eliminate the need for hypodermic needles for many therapeutics and traditional intramuscular vaccinations. It focuses on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. The company was founded by Sahan Ranamukharachchi, Iman Mansoor, Urs O. Häfeli, and Boris Stoeber in June 2014 and is headquartered in Vancouver, Canada.

Microdermics, Inc. designs, builds, tests, and manufactures proprietary hollow metal microneedles that will eliminate the need for hypodermic needles for many therapeutics and traditional intramuscular vaccinations. It focuses on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market. The company was founded by Sahan Ranamukharachchi, Iman Mansoor, Urs O. Häfeli, and Boris Stoeber in June 2014 and is headquartered in Vancouver, Canada.